Clinical study of Buyanghuanwu decotion and aspirin in treatment of aspirin resistance when transientischemic attack
- VernacularTitle:补阳还五汤联合阿司匹林治疗短暂性脑缺血发作时阿司匹林抵抗的临床研究
- Author:
Meifang JIANG
- Publication Type:Journal Article
- Keywords:
transient ischemic attack;
Buyanghuanwu decotion;
aspirin resistance
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(2):106-107,109
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe and compare the clinical efifcacy of buyanghuanwu decotion combined with aspirin in treatment of aspirin resistance when transient ischemic attack(TIA). Methods 80 patients with TIA from September 2010 to October 2013 in Affiliated Hospital of Weifang Medical College were selected according to the standards and divided into two groups, with 40 cases in each group. Experimental group were orally administered with buyanghuanwu decotion and aspirin. Control group were orally administered with clopidogrel and aspirin. The levels of arachidonic acid (AA) and adenosine diphosphate (ADP) before therapy and in the 60 th and 90 th treatment day were detected by turbidimetry, respectively. Follow-up studies were performed to observe the recurrence numbers of TIA, cerebral infarction cases and adverse events, such as mucocutaneous hemorrhage and hemafacia in two groups during therapy. Results The levels of AA and ADP were decreased constantly with the therapy time in both two groups. The levels of ADP and AA in experimental group before therapy and in the 60 th and 90 th treatment day were not signiifcantly different from those in control group. No signiifcant differences of reoccurrence rate and the cerebral infarction rate were found between the two groups. However, there was statically signiifcant difference in the occurrence of adverse events between the two groups (P<0.05). Conclusion The clinical efifcacy of the combined treatment of buyanghuanwu decotion with aspirin shows no signiifcant difference with the combined treatment of clopidogrel and aspirin, but with lower incidence rate of adverse events.
